In xenograft models of CRPC and enzalutamide-resistant PC patients, GLUT1 inhibition significantly reduced tumor volume and displayed synergistic effects with androgen receptor (AR)-targeted therapy [286]. The gene discussed is AR; the disease is neoplasm.